⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HRMY News
Harmony Biosciences Holdings, Inc. Common Stock
Harmony Biosciences to Participate in Upcoming Investor Conferences
businesswire.com
HRMY
Form 8-K
sec.gov
HRMY
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
businesswire.com
HRMY
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
businesswire.com
HRMY
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX ® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
businesswire.com
HRMY
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX ® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
businesswire.com
HRMY
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
businesswire.com
HRMY
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
businesswire.com
HRMY
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight
prnewswire.com
TAK
JNJ
CANF
AMGN
ABBV
NVS
BMY
AZN
BHC
LLY
UCB
LEO
REGN
XBI
IBB
JAZZ
MRK
SNY
GILD
INCY
PFE
LULU
PRTH
DRH
BIIB
TEVA
ARCT
HRMY
CRSP
NTLA
EDIT
SNOW
DDOG
CRM
GOOG
MSFT
AAPL
AMZN
TSLA
NVDA
META
NFLX
DIS
CMCSA
VZ
T
KO
PEP
MCD
SBUX
HD
EXAS
ILMN
BNTX
MRNA
XOM
CVX
BA
CAT
GE
IBM
INTC
CSCO
ADBE
QCOM
AMAT
MU
ORCL
ACN
COST
WMT
TGT
LOW
HON
GD
LMT
RTX
BAX
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
businesswire.com
HRMY